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1. Introduction 
Anderson’s Disease (AD)/Chylomicron Retention Disease (CMRD) (OMIM #607689) is a rare 
autosomal recessively inherited lipid malabsorption syndrome characterized by 
hypocholesterolemia associated with failure to thrive, diarrhea, steatorrhea and abdominal 
distension that presents most frequently in young infants. Charlotte Anderson first 
published a description of the disorder in 1961 [1] based upon observations of a young girl 
of seven months of age who manifested a characteristic macroscopic and microscopic 
appearance of the intestinal mucosa which was filled with fat. Forty two years later, in 2003, 
Jones and colleagues [2], in 8 families, identified mutations in the SAR1B gene, which 
encodes for the intracellular trafficking protein SAR1b, and proposed that this was the 
molecular defect in the disorder. The disease is very rare. From the first clinical description 
of the disease up to the identification of the causal gene, only 39 patients from 24 families 
were described in the literature [3-21]. From 2003 to the present, 23 new patients from 14 
additional families have been identified. In all, 16 different mutations in the SAR1B gene 
now have been described in 34 patients from 21 families [2, 22-27]. Here, we provide an 
overview of this disease, including the description of 4 new patients from 3 new families 
(one new mutation), and we describe the predicted molecular impact on the SAR1b protein 
of novel or previously-described mutations in the SAR1B gene. 
2. Clinical features 
The first symptoms of AD/CMRD, which most frequently occurr within a few months after 
birth, consist of failure to thrive, diarrhea with steatorrhea and abdominal distension. Of the 
62 patients described in the literature, only 4 were diagnosed as adults; two sisters presented 
with diarrhea that was found to have begun in infancy [21, 23], the third adult had severe 
neurological signs in infancy [6] and the past medical history of the last adult revealed some 
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clumsiness in walking and running and very loose bowel movements in infancy [7]. These 
patients may have spontaneously avoided the fat in their diets to minimize symptoms. Non 
specific malabsorptive diarrhea is present in almost all cases with steatorrhea, even when a 
low fat diet is observed [28]. The diagnosis is sometimes delayed (often for several years) 
because the symptoms are non-specific and are attributed to chronic diarrhea (cystic fibrosis 
or coeliac disease). Thus, 39/45 patients exhibited the first symptoms before one year of age, 
whereas only 21/52 received the proper diagnosis without undue delay. As consequence of 
diarrhea, failure to thrive (-1 to -4DS for height and/or weight) is also frequent (45/51 
patients) and persists if a low fat diet is not instituted. Other digestive symptoms, such as 
vomiting or a grossly distended abdomen are commonly observed. Usually, if a low fat diet 
supplemented with lipid soluble vitamins is instituted, the growth starts again; however, 
some patients with a delayed diagnosis do not attain a normal height and weight [29]. 
Tolerance to fat in the diet has been reported in a few cases [14, 16, 22, 24, 27]; however, in 
most instances, diarrhea begins again when fat is reintroduced in the diet [29]. 
Hepatic and neurological abnormalities, although sometimes reported in young patients, 
generally are tardive manifestations, particularly when the diagnosis and the 
implementation of dietary vitamin supplements are delayed. Several cases of transient 
hepatomegaly have been described [6, 9, 11, 16, 17, 22] and one or both amino- 
transaminases (ASAT and ALAT) are frequently reported to be increased (13/15 patients of 
Charcosset [22]) but confirmed hepatic steatosis are infrequent (three cases described) [11, 
25]. However, no instance of cirrhosis has been reported. In young adults or older patients, 
neurological abnormalities consist mainly of areflexia [11, 12, 14, 22]. In some cases, more 
severe neurological degeneration consisting of ataxia, sensory neuropathy and/or tremor 
has been reported [6, 7, 11, 19]. Mild defects in color vision and retinal function also have 
been observed [11, 14, 28] but no retinis pigmentosa has been reported. Acanthocytosis is 
very rare and usually transient [6, 12, 17, 27]. 
Mild muscular abnormalities have been described in several patients and consist mainly of 
muscular pain and cramps; one patient was described with myopathy [6]. Creatine kinase 
(CK) levels are often found to be elevated (1,5-2,5 times normal) [23, 27]. Jones et al (2003) 
have shown that high levels of SAR1B mRNA expression occurs in tissues other than 
intestine [2] and, therefore, extra-intestinal clinical manifestations might occurr in 
AD/CMRD. Silvain et al have described a cardiomyopathy in an adult and documented the 
accumulation of lipids in some muscle fibers [23]. Consequently, clinical evaluation and 
follow-up of these patients should include CK levels and cardiac examination. 
Poor mineralization and delayed bone maturation may be present and vitamin D levels may 
be normal or decreased [5, 12, 18, 21, 23, 28]. Several patients also have exhibited associated 
infectious diseases [14, 16]. 
AD/CMRD patients exhibit a particular recessive hypocholesterolemia which differs from 
other familial hypocholesterolemias. The hypocholesterolemia manifests itself by a decrease 
of plasma LDL (LDLc) and HDL (HDLc) cholesterol (both by approximately 50%) associated 
with a normal level of triglycerides (Table 1). The severe decrease of HDLc (the mean level 
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in patients is 0,49mM) associated with a normal triglyceride level is pathognomonic of AD, 
if all the secondary causes of malabsorption such as celiac disease, exocrine pancreatic 
insufficiency (cystic fibrosis or Shwachman-Diamond syndrome), and the Mc Kusick 
syndrome (small height and malabsorption with exactly the same lipid profile as AD) have 
been ruled out. Further, other causes of familial hypocholesterolemias must be carefully 
ruled out; for example, some patients with AD/CMRD have low levels of triglycerides and 
high levels of HDLc that are similar to those found in atypical abetalipoproteinemia [30, 31] or 
homozygous hypobetalipoproteinemia (data not shown). Plasma levels of vitamin E, 
measured before supplementation in patients diagnosed during the last decade, are usually 
low or very low (but detectable, from 0,5 to 6,8 µM, 3 of 19 patients had undetectable levels). In 
patients described previously, the undetectable levels were probably due to technical 
limitations (reported values range from 0, 23 to 11,3 µM, and 13 of 28 patients had 
undetectable levels). Mild decreases of vitamin A have also been found [5, 6, 11, 12, 18, 21, 24, 
27] but there are normal levels of other fat soluble vitamins in most of the AD/CMRD patients.  
 
Patients data All published cases Published cases with mutations 
N 62 34 
age at onset 56% < 3 mths, 87% < 1 year 53% < 3 mths,  84% < 1 year 
age at diagnosis 60% > 1 year,  23% > 10 years 50% > 1 year,  23% > 10 years 
major clinical data 
90% diarrhea, 88% failure to 
thrive 
90% diarrhea, 57% failure to 
thrive 
TC mM n=54     M=1,75    (0,86-3,38) n=34     M=1,81     (1,11-2,82) 
TG mM n=48     M=0,87    (0,36-2,06) n=33     M=0,92     (0,36-1,98) 
HDLc mM n=26     M=0,49    (0,32-0,83) n=23     M=0,50     (0,32-0,83) 
LDLc mM n=26     M=0,87    (0,26-1,61) n=23     M=0,88     (0,31-1,61) 
apoB g/l n=37     M=0,44    (0,20-0,82) n=21     M=0,49     (0,20-0,82) 
apoA1 g/l n=31     M=0,52    (0,26-0,90) n=18     M=0,52     (0,38-0,90) 
Vitamin E µM n=43     M=2,74      (0 – 11,3) n=23     M=2,81        (0 – 7,6) 
(TC: total cholesterol, TG: triglycerides, HDLc: HDL cholesterol, LDLc: LDL cholesterol) 
Table 1. Mean data for all the published cases 
In most cases, an essential fatty acid (FA) deficiency has been not investigated, nevertheless, a 
decrease of linoleic acid (C18:2 n-6) and normal levels of n-3 FA have been found in two files of 
patients [10, 28]. For all the patients, the lipid profiles of the heterozygous parents were normal. 
Four new cases of AD/CMRD in 3 families have recently been discovered (Table 2, 3). All the 
individuals presented with diarrhea and failure to thrive (4/4 patients). Interestingly, one of 
the patients presented with tremor at diagnosis (Table 2). The plasma lipids and vitamin E 
exhibit a wide range of levels and, in particular, the triglycerides and total and LDL 
cholesterol values which is an other characteristic of AD.  
The inability of the enterocytes to secrete chylomicrons and apoB 48 after a fat load is a 
common clinical feature of AD/CMRD, ABL (abetalipoproteinemia) and, generally, 
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homozygous FHBL (familial hypobetalipoproteinemia). When observed with video-
endoscopy, the intestine of AD/CMRD patients shows a white mucosa (“gelée blanche”). This 
typical white stippling, like hoar frosting, covers the mucosal surface of the small intestine 
(Fig 1A, B) even in the fasted state in contrast to healthy individuals. When intestinal 
biopsies from patients who have fasted are observed by light microscopy, they appear to 
have a normal number of villi of appropriate length. However, the enterocytes are 
overloaded with birefringent droplets in the cytoplasm (Fig 1 C, D) [1, 5, 6, 8, 9, 11, 12, 14, 
16-18, 20, 25, 27]. These droplets are present, mainly, in the upper one-third of the villus of 
the enterocyte and they stain positively with oil red O indicating that they are fat droplets 
(mainly triglyceride) (Fig 1D, E). In some cases, the droplets are seen to be present 
preferentially on one side of the villus as opposed to both sides, whereas, in other cases (or 
sometimes in the same case), they may be present on both sides [32]. When the biopsies are 
examined by electron microscopy, two types of lipid-containing structures, in fact, are 
observed in the cytoplasm which alter the normal architecture of the cells.Very large lipid 
droplets (1025 nm average diameter), not in a membrane-bound compartment, are present 
along with smaller lipoprotein–sized particles (305 nm average diameter) which are present 
in membrane-bound structures (Fig 2 A, B) [32]. This is in contrast to enterocytes in biopsies  
 
Intestinal endoscopy after a 12-hour fast. In contrast to what is observed in a normal subject (A), video-endoscopy of 
the duodenum (D) of patient AD2 (B), shows the typical « white hoary frosting » on the small intestinal mucosa. In 
contrast with a normal subject(C), light microscopy of the duodenal biopsy from AD2 (D) shows the typical vacuolated 
enterocytes (black arrows) that stain positively with oil red O (E, black arrows). Note the typical heterogeneous aspect 
of the villi either fat loaded (black arrows) or without lipid droplets (white arrows). 
Goblet cells are normal (D, arrow g). (C ×100; D ×400; E ×200). 
Figure 1. Intestinal endocopy after a 12-hour fast (A, B, C, D, E) (from A. Georges [27]) 
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from patients with ABL which exhibit only (or predominantly) the very large lipid droplets 
whereas the smaller lipoprotein-sized particles, in membrane bound structures, are absent. 
In the enterocytes of both AD/CMRD and ABL patients, the Golgi apparatus is often 
distended but it is, generally, empty and free of lipoprotein-like particles. Further, in 
AD/CMRD, lipoprotein-like particles are observed, although in only a few cases, in the 
intercellular spaces between the enterocytes in contrast to ABL where they are never 
observed in intercellular spaces.  
In addition to the lipid profiles of the patient and the parents, the diagnosis is supported by 
the absence of secretion of chylomicrons after a fat load, the presence of white duodenal 
mucosa upon endoscopy, the presence of cytosolic lipid droplets and lipoprotein-sized 
particles in the enterocytes of the intestinal biopsy and, finally, the discovery of a mutation 
in SAR1B gene. It should be noted, however, that the AD/CMRD phenotype has been 
observed in patients for which there is no mutation in the coding sequence of the SAR1B 
gene ([33] and unpublished data). 
3. Functions of the SAR1B protein 
SAR1 is a well-known GTPase (guanine tri-phosphatase) which belongs to the ARF (ADP-
ribosylation factor) family of small GTPases [34, 35]. SAR1 initiates the assembly of COPII 
(coat protein complex II) in the endoplasmic reticulum (ER) by binding to SEC12. Then, 
SAR1-GDP is converted into SAR1-GTP which undergoes a large conformational change in 
the two switch regions. The residue Threonine 56, in switch 1, forms bonds to the у 
phosphate and Mg2+ and the residue Glycine 78, in switch 2, binds to the у phosphate. The 
movements expose the amino terminal, amphipatic α1 helix (« the membrane anchor ») 
which then inserts into the ER membrane [36]. Mg2+ has an important regulatory role in this 
conformational change, mostly related to switch 1 [37]. The membrane-bound SAR1 recruits 
SEC23-SEC24 and triggers the formation of the pre-budding complex which then recruits 
SEC13-SEC31 to form the COPII vesicle [36, 38]. SEC24 interacts with specific cargo proteins 
and concentrates them into the COPII vesicle [39]. SAR1 GTP hydrolysis is stimulated by 
SEC23 and SEC31 and permits vesicle fission, allowing transport to the Golgi, and eventual 
disassembly of the coat for recycling of the components [40-42]. SED4p, a protein with 45% 
homology to SEC12p, accelerates the dissociation of SEC23-24 from the membrane if no 
cargo is transported with COPII vesicles and it has been proposed that this restricted 
disassembly might play a role in concentrating cargoes into COPII vesicles [43].  
The typical size of the COPII vesicles ranges from 60 to 70 nm in diameter, which would 
appear to prohibit these vesicles from carrying chylomicrons (250 nm average diameter) 
from the ER to the Golgi apparatus [44]. Another vesicle (350-500 nm in diameter), the pre-
chylomicron transport vesicle (PCTV), has been shown to be able to transport chylomicrons 
[45]. The PCTV is composed of several proteins: VAMP7 (vesicle-associated membrane 
protein 7) which is the v-SNARE (vesicle-associated soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor), apoprotein B48 (a cargo), FABP1 (also called liver fatty 
acid- binding protein, LFABP) (budding initiator), the fatty acid transporter CD36 (a fatty  
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Electron microscopy of duodenal biopsies of patients with AD. As shown for AD3 (A, B, C) and AD2 (D, E), two 
types of particles are apparent in the enterocytes in these patients (A, D): large lipid droplets, free in the cytoplasm (L), 
and smaller, lipoprotein-sized like particles (Lp), surrounded by a membrane. A higher magnification shows in (B) 
some individual lipoprotein-sized particles surrounded by a membrane (*)near a Golgi apparatus (G) which appears 
distended but devoid of particles and in (C, E) numerous lipoprotein-sized particles accumulated in membrane bound 
compartment (membrane, white arrow). The intercellular spaces are empty. The cell nucleus is labelled N. 
Figure 2. Electron microscopy of duodenal biopsies of patients with AD (from A. Georges ref 27) 
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Figure 3. Sequence alignment of SAR1B protein with functional regions 
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acid translocase) and the COPII proteins [46]. PCTV budding does not require GTP (and,  
consequently, SAR1) but rather ATP [44]. Further, VAMP7 is necessary for the fusion of the 
PCTV with the Golgi [44, 47]. The role of Sar1 in the budding of PCTV has been clarified, 
recently, in an elegant study by Siddiqi and Mansbach (2012) [47]. They showed that the 
binding of FABP1 to intestinal ER generates PCTV. A cytosolic multi-protein complex 
(composed of SAR1b, SEC13, SVIP (Small VPC/p97- Interactive Protein) binds all the FABP1 
which is subsequently liberated by the phosphorylation of SAR1b by PKCζ (Protein Kinase 
C Zeta).  
These findings raise a number of questions as to the mechanism by which SAR1B gene 
mutations could affect PCTV transport to produce AD/CMRD. In particular, it is not clear 
how mutations that are located in regions involved in the binding and hydrolysis of 
GDP/GTP (and for which the effect on COPII mediated transport is evident) would affect 
PCTV transport (see below: Predicted impact of the mutations). Since SAR1b plays a role in 
both vesicle budding and vesicle fusion to the Golgi apparatus, further studies will be 
necessary to completely understand the  apparently multiple roles that SAR1b plays in 
PCTV transport. Recently, L Jin and coll showed that the ubiquitylation by CUL3-KLHL2 
allow the formation of COPII vesicle of a size sufficient to transport collagen (300-400 nm) 
[48]. It is of interest to know whether this mechanism also could permit the transport of 
chylomicrons. These recent data provide novel insights into the possible mechanisms for the 
transport of chylomicrons (either by PCTVs or COPII vesicles) and are very interesting 
because impaired COPII function results not only in AD/CMRD but also in collagen 
deposition defects [49] and lenticulo-structural dysplasia (SEC23A mutation). However, 
given the ubiquitous expression and essential roles of COPII components such as SAR1 and 
SEC23 as well as other proteins involved in trafficking between ER and Golgi, it is still not 
entirely clear as to how mutations in these proteins produce diseases with such marked 
tissue specific effects and low incidence.  
4. Structure of the SAR1b protein 
Although the SAR1 protein is included in the GTPase superfamily (and, in particular, the 
RAS superfamily) members of which are present in most living cells, from bacteria to 
vertebrates, it is only slightly related to other RAS or ARF proteins and is distant from the 
RAB/YPT1/SEC4 subclass [50, 51].  SAR1 is conserved from an evolutionary standpoint and 
appears to present in all eukaryotes. However, whereas yeast and insects have a single 
SAR1 protein,  higher organisms express two forms, SAR1b and SAR1a (both with 198 
amino acids), which differ by 20 amino-acid residues [52].The function of SAR1a has not 
been elucidated yet and, to date, no variant in the SAR1A gene has been described. The 
sequence alignment of SAR1b as compared to SAR1p (Figure 3) illustrates the different 
regions that are highly conserved across species and shows the different functional motifs in 
SAR1b that participate in vesicle budding, in GDP/GTP binding and hydrolysis and in 
interactions with other COP proteins.  
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Five X-ray crystallographic-derived structures for SAR1b bound to GDP or GTP, alone or 
complexed with other COPII components, have been deposited in the Protein Data Bank. 
Three of these structures are derived from S. cerevisiae (yeast) recombinant protein and two 
from Cricetulus griseus (hamster) recombinant protein.  These structures provide insights 
into the structural changes that SAR1b may undergo upon GDP/GTP binding as well as 
demonstrating which parts of the protein constitute interfaces with other COPII 
components. No X-ray derived structures of SAR1b complexed with components of the 
PCTV are available to our knowledge. There is also one X-ray derived structure for SAR1a 
using human recombinant protein. 
 
Using the 1F6B model Cricetulus griseus SAR1b [53]  
(which lacks the first twelve AA)  
and Swiss pdb Viewer:  
two residues were modified (I80V, V163I)  
in order to produce a structural module  
having a sequence identical to that of human  SAR1b. 
In yellow: β strands 
In blue: α helixes 
In white: loops 
In green: GDP 
Figure 4. Three dimensional structure of SAR1B protein 
The X-ray structures show that SAR1b has six central β strands (5 parallel, β2 antiparallel) 
that are sandwiched between three α helixes on each side (Figure 4). In SAR1-GDP (the 
inactive form), the α1helix is retracted into a pocket formed by the β2- β3 hairpin. The β 
strands 1-2-3 are approximately parallel to the membrane allowing their juxtaposition with 
the membrane (the N and C terminus and β2- β3 hairpin would participate in this 
membrane interaction) [36]. The Mg2+ ion is coordinated by an oxygen atom of the  
phosphate of the GDP and the hydroxyl oxygen of Threonine residue 39 (in SAR1-GDP) 
[37]. Many H bonds stabilize the structure and could be altered by mutations (see discussion 
below), for example Ser 179 with Asp 137 and Leu 181 [2]. 
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The X-ray data also provide insights into the roles played by the different parts of the 
structure in SAR1b functions (see the protein alignment Figure 3). The amino- (N) terminal 
part of SAR1b contains the STAR (SAR1 NH2 Terminal Activation Recruitment) motif, a 
hydrophobic sequence of amino acids (AA) (1-9), a structure different from other ARF 
superfamily GTPases, which recruits SEC12, and the α1 amphipathic helix (AA 15-19, 
residues VLNFL). The role of the α1 amphipathic helix is fundamental as demonstrated by 
the loss of all export activity of SAR1B following the substitution of the 4 hydrophobic AA 
by 4 Alanine [53]. Between the STAR motif and the α1 helix, a short domain (AA 9-14, 
YSGFS) participates in deforming the ER membrane [38]. Three other regions contact the 
membrane, one each in the N- (AA 1-25) and carboxyl- (C) (AA 195-198) terminii and a 
central motif in the β2- β3 strand (AA 65-70) [36, 38]. There is one motif that recognizes the 
guanine base (AA 134-137, NKXD) and two active sites for GTP hydrolysis (AA 32-38, motif 
GXXXXGK and AA 75-78, motif DXXG) [54]. Close to the GTP hydrolysis site, Threonine 39 
is a highly conserved residue and the substitution T39N inhibits SAR1 function by 
interfering with activation by SEC12 [53]. 
The two switch regions (AA 48-59 and AA 78-94) contain two very important residues, the 
Threonine at position 56 and the Glycine at position 78, respectively [53]. A second unique 
structural region of SAR1, not observed in the ARF GTPases, is a long surface-exposed loop 
(AA 156-171) which connects the α4 helix and the β6 strand and which regulates the 
function of SAR1b. The substitution Thr158Ala abolishes the activity of SAR1 [53]. A specific 
C-terminal motif (AA 171-181, PXEVFMC/VSV/L), present in the β6 strand, targets SAR1b to 
the ER [55].  
The three-dimensional structure was obtained by crystallography [36, 53] and then by a 
computational approach. By crystallography (without the nine first and the 48-55 residues ), 
SAR1-GDP appeared as a dimer [37, 53]. Nothing is available about an in vivo GTPase 
activity with this dimer structure. Moreover, Long and coll (2010) showed that SAR1b may 
function as a monomer [56], so we will only consider the monomer form.  
5. Predicted impact of the mutations in the SAR1B gene on the structure 
and function of the protein  
Currently, including the 4 new cases belonging to 3 new families reported here (one new 
missense mutation), mutations in the SAR1B gene have been established for 43 individuals 
with AD/CMRD (belonging to 24 families). There are only 17 unique mutations. The 
majority of individuals are homozygous for their mutation (38/43) and 5 individuals from 4 
families are compound heterozygous. There are a total of 7 nonsense and 10 missense 
mutations (Table 2). Since structural information concerning SAR1b in PCTV vesicles is not 
available, the discussion of the possible effects of SAR1B gene mutations upon protein 
function will be limited to the COPII vesicle transport system.  
Recently we identified the same mutation (del exon2) as the Algerian family (n°2) in 3 
patients from 2 Tunisian families (to be published). 
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SAR1B DNA variant 
protein 
mutation 
ethnic origin 
Family 
number
sex status age dg references 
exon 2 c.32 G>A p.G11D thaï  1 M comp Hz 11m 24 
(1-58 bp) c.-4482_58 +1406 del 
5946 ins 15bp 
(named del exon 2) 
p.M1_H43del algerian 2 F Ho 6y 22 
  p.M1_H43del algerian 2 M Ho 8y 22 
exon 3 c.83_84 delTG p.L28R fsX34 french canad 3 F comp Hz ? 2, 11 
(59-178bp) c.83_84 delTG p.L28R fsX34 morrocan 4 F Ho 7m 25 
  c.83_84 delTG p.L28R fsX34 morrocan 5 F Ho 8m 27 
  c.92 T>C p.L31P morrocan 6 M Ho 3m this article 
  c.92 T>C p.L31P morrocan 6 M Ho 15y this article 
  c.109 G>A p.G37R algerian 7 F Ho 3,5y 2, 13 
  c.109 G>A p.G37R algerian 7 M Ho 3m 2, 13 
  c.109 G>A p.G37R morrocan 8 M Ho 3y 2, 12 
  c.142 delG p.D48T fsX17 turkish 9 M Ho 10m 27 
  c.142 delG p.D48T fsX17 turkish 9 F Ho 1m 27 
exon 4 c.184 G>A p.E62K tunisian 10 F Ho 7y 26 
(179-244bp) c.224 A>G p.D75G thaï  1 M comp.Hz (see family 1 exon 2) 
exon 6 c.349-1 G>C p.S117K160del italian 11 M Ho 12y 2, 19 
(349-480bp) c.349-1 G>C p.S117K160del italian 11 M Ho 19y 2, 19 
  c.364 G>T p.E122X turkish 12 M Ho 3m 22 
  c.364 G>T p.E122X turkish 12 F Ho 6y 22 
  c.364 G>T p.E122X turkish 12 F Ho 8y 22 
  c.364 G>T p.E122X turkish 12 M Ho 11y 22 
  c.409 G>A p.D137N french canad 13 M Ho ? 2, 11 
  c.409 G>A p.D137N french canad 13 F Ho ? 2, 11 
  c.409 G>A p.D137N french canad 3 F comp.Hz (see family 3 exon 3) 
  c.409 G>A p.D137N french canad 14 M Ho 3m 22 
  c.409 G>A p.D137N french canad 14 M Ho 2m 22 
  c.409 G>A p.D137N french canad 15 M Ho 3m 22 
  c.409 G>A p.D137N french canad 16 F comp Hz 2w 22 
  c.409 G>A p.D137N french canad 16 M comp Hz 3,5m 22 
  c.409 G>A p.D137N french canad 17 F Ho 50y this article 
  c.409 G>A p.D137N caucasian 18 M Ho 8m this article 
exon 7 c.499 G>T p.E167X caucasian 19 F Ho 34y 21, 23 
(481-597bp) c.499 G>T p.E167X caucasian 19 F Ho 38y 23 
  c.536 G>T p.S179I pakistan 20 F comp Hz 6m 2 
  c.537 T>A p.S179R french canad 16 F comp.Hz (see family 16 exon 6) 
  c.537 T>A p.S179R french canad 18 M comp.Hz (see family 16 exon 6) 
  c.537 T>A p.S179R french canad 21 F Ho 10y 22 
  c.537 T>A p.S179R french canad 21 M Ho 2m 22 
  c.537 T>A p.S179R french canad 22 F Ho 5m 22 
  c.542 T>C p.L181P pakistan 20 F comp.Hz (see family 20 exon 7) 
  c.554 G>T p.G185V portuguese 23 F Ho 2y 22 
  c.555-557 dupTTAC p.G187LfsX13 turkish 24 F Ho 1y 2, 16 
  c.555-557 dupTTAC p.G187LfsX13 turkish 24 M Ho 1y 2, 16 
(Ho: homozygous, comp Hz: compound heterozygous, age dg: age at diagnosis, m months, y years, w weeks) 
Table 2. All published mutations in SAR1B gene 
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5.1. Nonsense mutations 
Among the seven non-sense mutations, one deletes exon 2 (p.1-4482_58+1406 del 5946 ins 
15bp, named “del exon 2”) and one eliminates exon 6 (p.S117K160del), two are stop codons 
(p.E122X, p.E167X) which lead to truncated proteins, and two deletions and an insertion 
produce frameshifts followed by stop codons (p.L28RfsX34, p.D48TfsX17, p.G187LfsX13) 
leading to truncated proteins and modified C-terminal sequences. The major deletion 
(5943bp) of exon 2 (family 2 and new Tunisian patients) potentially leads to 4 different 
proteins [22] each of which lacks part of the N-terminus. The largest fragment lacks the first 
43 residues, including the STAR motif, the α1 helix, the active site for GTP hydrolysis and 
Threonine 39. The deletion of exon 6 eliminates the recognition site for the guanine base (AA 
134-137) thus abolishing the function of SAR1b. The five other nonsense mutations 
(resulting in stop codons) produce truncated proteins lacking the C-terminus. The shortest 
fragment is predicted to have about 33 AA and the longest contains 187/198 AA but, 
interestingly, all are predicted to abolish the function of the protein in the same manner. 
This suggests that the C terminal part of the protein plays a major role in the function of 
SAR1. 
5.2. Missense mutations 
The Swiss-pdb Viewer 3.1 program ([57], available on http://www.expasy.org/spdbv/) was 
used to calculate atomic resolution structural models for SAR1b having missense mutations 
(Table 3). First, using the 1F6B model [53] and PDB for Cricetulus griseus SAR1b (which lacks 
the first twelve AA and the 48-55 residues), two residues were modified (I80V, V163I) in 
order to produce a structural module having a sequence identical to that of human  SAR1b. 
The effects of the missense mutations of AD/CMRD on this “humanized” structure were 
then modelled.  
All the missense mutations are located on the exterior of the three dimensional structure, in 
strategic places near the recognition, binding and hydrolysis sites for the guanine base (in 
the N- and C-terminii) and/or affect a highly conserved residue in SAR1/Arf proteins. From 
the N- to the C- terminus the predicted effects may be summarized as the following (Figure 
3). The p.G11D mutation is located in the membrane interacting site (anchorage of the N-
terminal part of the molecule) and probably prevents binding to SEC12 and fixation to the 
ER membrane. The substitution G11P, associated with Y9F and S14F, has been described as 
being deleterious for vesicle release [38], however no model is available for this mutation 
(since the coordinates of the first 12 residues of the protein could not be established by the 
X-ray study leading to the 1F6B structure). The new mutation p.L31P affects the AA just 
before the active site of GTP and could decrease the GTP hydrolysis. The substitution of a 
linear (leucine) by a cyclic (proline) residue could lead to steric hindrance (Figure 5). The 
p.G37R and the p.D75G mutations are located in two different GDP hydrolysis sites. 
Replacement of glycine 37 by arginine creates steric hindrances with C178 and N134 and the 
replacement of the aspartic acid 75 by glycine abolishes the H bond with L38. All four of 
these mutations reduce or eliminate the affinity of SAR1b for GDP/GTP and are expected to  
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Using the 1F6B model Cricetulus griseus SAR1b [53] and Swiss Pdb Viewer  
Figure 5. Localization of missense mutations in the three-dimensional structure of SAR1B 
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Energy kJ/mol a
Grantham 
distance b
Consequence of 
mutation on 
prot. (concerned 
residue) a 
Residue conservation c 
PolyPhen 
prediction 
(Score) d 
SIFT 
prediction 
(Score)e   
Sar1b 
prot. 
Sar1 
prot.
Sar1/ Arf 
family 
prot. 
Small GTP 
binding 
prot. 
wild 
type 
-9 749                 
G11D 
no 
modelisation 
94 no modelisation ? 0 0 0 
possibly 
damaging 
(0,927) 
affect 
protein 
(0,03) 
L31P -6560 98 
steric hindrance 
(Val97) 
 + c c c 
probably 
damaging  
(1,0) 
affect 
protein 
(0,02) 
G37R 75988 125 
steric 
hindrances 
(Asn134, 
Cys178) 
 +  +  +  + 
probably 
damaging  
(1,0) 
affect 
protein 
(0,00) 
E62K -7777 56 
loss of one H-
(Glu63) 
 + c  + 0 
possibly 
damaging 
(0,955) 
affect 
protein 
(0,00) 
D75G -9406 94 
loss of one H-
(Lys38) 
 +  +  +  + 
probably 
damaging 
(0,99) 
affect 
protein 
(0,00) 
D137N -10 086 23 
loss of one H-
bond (GDP) 
 +  +  +  + 
probably 
damaging  
(1,0) 
affect 
protein 
(0,00) 
S179I  -8867 142 
loss of : one 
weak H-bond 
(GDP) and one 
H-bond 
(Asp137) 
 +  +  s  0 
probably 
damaging 
(1,0) 
affect 
protein 
(0,00) 
S179R  -7550 110 
loss of : one 
weak H-bond 
(GDP) and one 
H-bond 
(Asp137) 
   +  s  0 
probably 
damaging 
(1,0) 
affect 
protein 
(0,00) 
L181P -9023 98 
steric 
hindrances with 
GDP 
c 0 0 0 
beningn 
(0,281) 
affect 
protein 
(0,00) 
G185V 127 288 109 
Steric hindrance 
(Met177) 
 +  +  +  0 
probably 
damaging 
(1,0) 
affect 
protein 
(0,00) 
 
a Swiss Pdb Viewer 3.7 based upon the template 1F6b lacking the first 12 residues of SAR1b C.g. (resolution: 1,70Å,  
R value: 0,220, homolgy 98,9%) modified (p.I80V and p.V163I: homology 100% ) 
b Grantham distance (Alamut ) 
c http://www.ebi.ac.uk/clustalw/ 
residue conservation: +, identical; c, conserved substitution; s, semi conserved substitution 
d PolyPhen-2 v2.2.2r395 http://genetics.bwh.harvard.edu/pph/ 
e Sorting Intolerant From Tolerant: http://blocks.fhcrc.org/sift/SIFT.html 
Table 3. Molecular impact of missense mutations 
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affect the stability of the protein. The substitution p.E62K affecting a well-conserved AA 
belongs to some residues forming the interface with SEC23 [36], abolishes the H-bond with 
Glu63 and is predicted to be deleterious by “in silico” analysis (Polyphen, available on 
http://genetics.bwh.harvard.edu/pph2/ [58] and SIFT available on http://sift.jcvi.org/ [59-
63]). A H-bond with the guanine in the guanine recognition site is abolished by the p.D137N 
mutation (Figure 5). Similarly the p.S179I and p.S179R mutations abolish the H-bonds with 
Asp 137 and with the guanine base. The substitution of a leucine for a proline (L181P) leads 
to steric hindrance with the guanine base and p.G185V modifies a highly conserved residue 
in the Arf/Sar1 family and is predicted to be deleterious by “in silico” analysis (Polyphen, 
SIFT). The last four mutations modify the α helix and β strands in the C-terminus and could 
affect the stability as well as the conformation of the protein.  
6. Possible founder effects: 
Founder effects are likely in the North African and French Canadian families (Table 2); it is 
likely that the same founder effect is responsible for the mutations of the North African 
patients (del exon 2, c.109 G>A). However, it is more uncertain for the c.409G>A and 
c.83_84delTG mutations, since the pedigrees of these families are not available. Perhaps 
there are hot spots, or different founder effects at the same place in the gene.  
7. The biological and clinical impact of SAR1b mutations: 
Table 4 provides the lipid profiles of the patients for which mutations in SAR1B have been 
established. As is typical for individuals affected with AD/CMRD, the mean values of total 
and HDL-cholesterol, apoAI and apoB are decreased, LDL-cholesterol is mildly decreased 
and triglycerides are in the normal range, however there is a large range of values for each 
of these parameters. As previously discussed, some patients present with low triglycerides 
or apoB levels and could be confused with atypical abetalipoproteinemia (familes 7, 12), and 
those with normal HDL cholesterol (family 10) could be confused with heterozygous FHBL. 
In homozygous patients, missense mutations are more frequent (12 families) than nonsense 
(8) and are as severe as nonsense mutations, except for the patient in family 10 (p.E62K) who 
has a normal HDL cholesterol level. The clinical data are not different among patients with 
different mutations. Several patients have been diagnosed later (adult or teenager) probably 
because of a mild intestinal syndrome and false diagnoses. Nevertheless, among the late 
diagnoses (10 patients after 10 years of age), only 3 have a missense mutation.  
It has been suggested previously [22] that there is no apparent correlation between the 
genotype and the phenotype in AD/CMRD patients. For example, patients (from different 
families) with the same homozygous SAR1B mutation (for example the D137N mutation) 
exhibit different lipid profiles and vitamin E levels as do patients from the same families with 
the same mutations (the E122X and the S179R mutations). It is possible that modifier genes 
could be a cause of the different phenotypes. For example, a decrease in the transcriptional 
factor SREBP (Sterol Regulatory Element Binding Protein) has been shown to block the 
incorporation of SCAP (SREBP chaperone) in COPII vesicles and an acute depletion of 
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cellular cholesterol concentration has been shown to decrease COPII transport [64, 65]. Other 
genes that modulate cholesterol homeostasis could interfere such as MTTP (microsomal 
triglycerides transfert protein), APOB, ABCG5/G8 (ATP Binding Cassette G5/G8).  
 
mutation ethnic origin family sex status TC TG HDLC LDLC apoB apoA1 vitE references 
p.G11D thaï  1 M comp Hz 1,81 1,29 0,54 0,43 1,5 24 
p.M1_H43del algerian 2 F Ho 2,01 1,44 0,32 1,04 0,5 0,42 3,3 22 
p.M1_H43del algerian 2 M Ho 2,32 0,78 0,4 1,57 0,55 0,45 2,6 22 
p.L28R fsX34 french canad 3 F comp Hz 2,2 0,73 1,4 2, 11 
p.L28R fsX34 morrocan 4 F Ho 1,45 0,77 0,36 0,73 0,39 0,4 1,2 25 
p.L28R fsX34 morrocan 5 F Ho 2,31 1,36 0,7 1 0,82 0,5 2,4 27 
p.L31P morrocan 6 M Ho 1,96 0,89 0,77 0,79 0,37 0,91 1,34 this article 
p.L31P morrocan 6 M Ho 2,09 0,93 0,59 1,31 3,75 this article 
p.G37R algerian 7 F Ho 1,26 0,67 0,2 0,39 7,6 2, 13 
p.G37R algerian 7 M Ho 1,79 1,44 0,33 0,38   2, 13 
p.G37R morrocan 8 M Ho 1,55 0,59 0,36 0,64 2,9 2, 12 
p.D48T fsX17 turkish 9 M Ho 2,61 1,24 0,57 1,48 0,56 0,7 4,4 27 
p.D48T fsX17 turkish 9 F Ho 2,72 1,36 0,83 1,28 0,43 0,9 6,8 27 
p.E62K tunisian 10 F Ho 2,59 1,3 1,14 0,4   26 
p.D75G thaï  1 M comp Hz    24 
p.S117K160del italian 11 M Ho 2,07 0,94 0,52 0,78 1 2, 19 
p.S117K160del italian 11 M Ho 2,43 1,28 0,7 1,22 5 2, 19 
p.E122X turkish 12 M Ho 1,99 0,43 0,57 1,23 0,36 4,71 22 
p.E122X turkish 12 F Ho 1,26 0,5 0,53 0,51 0,38 0,43 0,88 22 
p.E122X turkish 12 F Ho 1,37 0,72 0,39 0,66 0,33 0,51 1,44 22 
p.E122X turkish 12 M Ho 1,36 0,45 0,45 0,71 0,35 0,59 1,42 22 
p.D137N french canad 13 M Ho 1,85 0,94 0 2, 11 
p.D137N french canad 13 F Ho 2,08 0,59 1,6 2, 11 
p.D137N french canad 2 F comp Hz    2, 11 
p.D137N french canad 14 M Ho 1,3 0,45 0,49 0,61   22 
p.D137N french canad 14 M Ho 0,86 0,37 0,38 0,31   22 
p.D137N french canad 15 M Ho 1,24 0,82 0,41 0,46   22 
p.D137N french canad 16 F comp Hz 1,39 0,91 0,36 0,62   22 
p.D137N french canad 16 M comp Hz 1,11 0,54 0,45 0,42   22 
p.D137N french canad 17 F Ho 2,52 1,35 0,53 1,38   this article 
p.D137N caucasian 18 M Ho 1,41 0,85 0,35 0,68 0,24 0,57 2,5 this article 
p.E167X caucasian 19 F Ho 1,86 0,43 0,44 0,57 <1 21, 23 
p.E167X caucasian 19 F Ho 2,15 0,36 0,55 0,62 <1 23 
p.S179I pakistan 20 F comp Hz 1,4 0,79 0,44 0,6 0,59   2 
p.S179R french canad 16 F comp Hz    22 
p.S179R french canad 16 M comp Hz    22 
p.S179R french canad 21 F Ho 2,82 1,36 0,59 1,61   22 
p.S179R french canad 21 M Ho 1,5 0,78 0,56 0,59   22 
p.S179R french canad 22 F Ho 1,78 1,28 0,56   22 
p.L181P pakistan 20 F comp Hz    2 
p.G185V portuguese 23 F Ho 2,36 1,98 0,49 0,98 0,61 0,46 2,5 22 
p.G187L fsX13 turkish 24 F Ho 2 1,6 0,7 0,5 6,6 2, 16 
p.G187L fsX13 turkish 24 M Ho 1,5 1,5 0,5 0,5 3,6 2, 16 
(TC total cholesterol, TG triglycerides, LDLc LDL cholesterol, HDLc HDL cholesterol : mM;  apoB, apoA1: g/l; vitE 
vitamin E: µM) 
Table 4. Biological data in described cases with mutations 
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Recently a polymorphism of PCSK9 (proprotein convertase subtilisin/kexin type 9), 
p.L15_16insL, has been reported in an AD patient [27]. This polymorphism is frequent (25% 
heterozygous in normal individuals and 34% in cases of HBL) and weakly 
hypocholesterolemic (-14%) [66]. Further, mutations or polymorphisms in other COPII and 
PCTV genes could contribute to the different phenotypes by modifying the network of all 
their corresponding proteins. However, none of these mutations have been described in 
cases of AD/CMRD. The search for polymorphisms in multiple proteins is very time-
consuming but could be facility by the new sequencing methods. Rare polymorphisms in 
the coding regions of the SAR1B and SAR1A genes have been described but none of these 
has been observed in the SAR1A gene in any of our patients and only one polymorphism 
(heterozygous) has been found in the SAR1B gene (L45L) in our patients. This 
polymorphism is found with the same frequency in the patients as in normal individuals 
(0,18 versus 0,19, respectively). The impact of this polymorphism has not been studied. 
8. Management of AD/CMRD (for details, see the guidelines of Peretti, 
2010 [29]) 
Treatment consists primarily of a low fat diet, with the appropriate amounts of n-6 and n-3 
fatty acids, supplemented with fat soluble vitamins. The failure to thrive of the children is 
the most important clinical feature and catch-up growth is not observed systematically [29]. 
The neurological and ophtamological complications may be less severe than in other familial 
hypocholesterolemias and may depend upon the levels of the fat soluble vitamins and when 
vitamin supplementation is instituted. Myolysis and cardiac abnormalities have been 
observed in some AD/CMRD patients [23] and consequently, measurement of the serum CK 
level should be included in the evaluation and follow-up of the patients. A moderate degree 
of fat liver is common, but until now no case of cirrhosis has been published.  
9. Conclusions and future prospects 
Significant advances in the diagnosis of AD/CMRD and in the understanding of lipoprotein 
secretion have occurred over the last decade. However, many questions remain to be 
answered.  SAR1b is a ubiquitous protein, essential for the trafficking of proteins between the 
ER and the Golgi. Why do the mutations in SAR1B, that have been reported to date, 
apparently affect only the intestine and the transport of chylomicrons in the enterocyte? 
Although an increase of SAR1A mRNA was measured in enterocytes containing mutated 
SAR1B [27], the AD/CMRD phenotype was still manifested by a lack of chylomicron 
secretion. Under what conditions, if any, could SAR1a replace SAR1b? Is SAR1a the veritable 
GTPase for COPII vesicles? Do some mutations or polymorphisms in other regulator genes 
explain the lack of correlation between genotype and phenotype in AD/CMRD? There are 
some CMRD patients without mutations of SAR1B, SAR1A, VAMP7, MTTP genes 
(unpublished data). What gene mutations could explain the AD/CMRD phenotype in these 
patients? Novel technologies (such as whole exome and whole genome sequencing) may 
provide a better understanding of this disease and open novel diagnostic approaches. 
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